Long-Term Treatment with Testosterone Undecanoate (TU) Injections Improves Urinary and Sexual Functions and Quality of Life (QoL) Independent of Age

Program: Abstracts - Orals, Poster Preview Presentations, and Posters
Session: MON 0001-0021-Effects of Regulating Sex Hormone Levels in Men
Clinical
Monday, June 23, 2014: 1:00 PM-3:00 PM
Hall F (McCormick Place West Building)

Poster Board MON-0019
Ahmad Haider, MD, PhD1, Aksam A Yassin, MD, PhD2, Gheorghe Doros, PhD3, Abdulmaged M Traish, PHD4 and Farid Saad, DVM, PhD5
1Private Urology Practice, Bremerhaven, Germany, 2Institute of Urology and Andrology, Norderstedt, Germany, 3Boston University School of Public Health, Boston, MA, 4Boston University School of Medicine, Boston, MA, 5Bayer Pharma AG, Berlin, Germany
Objective: Hypogonadism is a risk factor for a host of diseases. This study analysed effects of testosterone replacement therapy (TRT) in hypogonadal men on urinary and sexual functions and QoL. 

Material and Methods: Two pooled, prospective, cumulative registry studies in 561 men (age: 58.55 ± 7.59 years) with T levels below 12.1 nmol/L.  450 men were aged ≤ 65 years (Group Y), 111 were > 65 years (Group O). They received parenteral TU 1000 mg/12 weeks following an initial 6-week interval for up to six years. The International Prostate Symptom Score (IPPS), International Index of Erectile Function-Erectile Function Domain (IIEF-EF, maximum score: 30) and Aging Males’ Symptoms Scale (AMS) were assessed at every visit. Post-void residual urine volume (PVR) as well as prostate volume were measured by ultrasonography. 

Results: Prostate volume increased in Group Y from 26.77±9.4 to 31.58±10.9 ml (p<0.0001), in Group O from 33.85±8.66 to 39.95±7.6 ml (p<0.0001). 

IPSS improved in Group Y 7.74±5 to 3.89±3.12 (p<0.0001), in Group O from 10.7±4.07 to 4.63±2.63 (p<0.0001). These changes were statistically significant vs. previous year for all six years in Group Y and the first five years in Group O and were then maintained throughout the observation period. 

PVR declined in Group Y from 34.87±23.12 to 16.72±6.74 ml (p<0.0001), in Group O from 41.46±23.48 to 18.84±5.75 ml (p<0.0001). 

IIEF improved in Group Y from 14.94±7.34 to 24.21±4.39 (p<0.0001), in Group O from 11.87±7.58 to 22.12±6. 41 (p<0.0001). These changes were statistically significant vs. previous year for the first four years in Group Y and the first two years in Group O and were then maintained throughout the observation period. 

AMS improved in Group Y 53.53±9.47 to 21.68±6.88 (p<0.0001), in Group O from 54.99±9.02 to 23.45±7.91. These changes were statistically significant vs. previous year for the first three years in both groups and were then maintained throughout the observation period.

C-reactive protein (CRP) as a marker of inflammation dropped in Group Y from 4.04±6.34 to 0.75±1.06 (p<0.0001), in Group O from 2.65±3.75 to 0.71±0.51 mg/dl.  

Conclusions: Despite an expected increase in prostate volume, TRT in both younger and older hypogonadal men produced sustainable improvements in urinary function with parallel improvements in sexual function and QoL. These effects are closely interrelated and may be partly mediated through anti-inflammatory effects of T.

 

Disclosure: AH: Speaker, Bayer Schering Pharma, Speaker, Takeda. AAY: Speaker, Bayer Schering Pharma, Speaker, Ferring Pharmaceuticals. GD: Coinvestigator, Bayer Schering Pharma. FS: Employee, Bayer Schering Pharma. Nothing to Disclose: AMT

*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting

Sources of Research Support: Bayer Pharma AG provided partial financial support for data entry and statistical analyses.